Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10469
Title: Alterations in vascular architecture and permeability following OXi4503 treatment.
Authors: Chan, Lie Sam;Malcontenti-Wilson, Caterina;Muralidharan, Vijayaragavan;Christophi, Christopher
Affiliation: Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia. l.chan11@pgrad.unimelb.edu.au
Issue Date: 1-Jan-2008
Citation: Anti-cancer Drugs; 19(1): 17-22
Abstract: OXi4503 retards tumor growth in a dose-dependent manner and improves survival in a murine model of colorectal liver metastases. This agent causes extensive vascular shutdown by selectively altering the tubulin cytoskeleton within the endothelial cells of tumor vessels. The destruction of tumor vessels is incomplete, however, and tumor revascularization occurs after the treatment. This study evaluates the pattern of microcirculatory changes and alterations to the ultrastructural properties of the tumor vasculature that result from OXi4503 treatment. Male CBA mice were induced with liver metastases via an intrasplenic injection of a murine-derived colorectal cell line. After administering a single intraperitoneal dose of OXi4503, changes in tumor perfusion, microvascular architecture and permeability were assessed at various time points. One hour after a 100-mg/kg dose of OXi4503, a significant decrease in the percentage of tumor perfusion (63.96+/-1.98 in controls versus 43.77+/-2.71 in treated mice, P<0.001) was observed, which was still evident 5 days after the treatment. Substantial tumor microvascular damage and minimal normal liver injury were observed. Tumor vascular permeability was significantly elevated 45 min after the OXi4503 treatment (67.5+/-3.60 in controls versus 80.5+/-2.24 microg/g, P<0.05). The findings suggest that OXi4503 selectively targets tumor vessels and causes immediate microvascular destruction. Even at the maximum tolerated dose, however, residual patent tumor vessels were still present after treatment, implying incomplete tumor destruction. A combination of OXi4503 with other chemotherapeutic modalities might achieve complete tumor eradication and improve long-term survival.
Internal ID Number: 18043126
URI: http://ahro.austin.org.au/austinjspui/handle/1/10469
DOI: 10.1097/CAD.0b013e3282f077a1
URL: http://www.ncbi.nlm.nih.gov/pubmed/18043126
Type: Journal Article
Subjects: Angiogenesis Inhibitors.pharmacology
Animals
Blood Vessels.drug effects.pathology
Capillaries.drug effects.pathology
Capillary Permeability.drug effects
Carcinogens
Colorectal Neoplasms.chemically induced.pathology
Dimethylhydrazines
Diphosphates.pharmacology
Evans Blue
Laser-Doppler Flowmetry
Liver Neoplasms.blood supply.secondary
Male
Mice
Mice, Inbred CBA
Microscopy, Confocal
Microscopy, Electron, Scanning
Regional Blood Flow.drug effects
Stilbenes.pharmacology
Tissue Fixation
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.